Literature DB >> 25427145

Development and characterization of six new human papillary thyroid carcinoma cell lines.

Ying C Henderson1, Soon-Hyun Ahn, Junsun Ryu, Yunyun Chen, Michelle D Williams, Adel K El-Naggar, Mihai Gagea, Rebecca E Schweppe, Bryan R Haugen, Stephen Y Lai, Gary L Clayman.   

Abstract

CONTEXT: Cell lines are a widely used tool in cancer research. However, despite the relatively high incidence of papillary thyroid carcinoma (PTC), there are only four PTC cell lines available for international research audience.
OBJECTIVE: The objective of this study was to establish and characterize new PTC cell lines that represent primary tumor biology. Surgical specimens were obtained to generate PTC cell lines. Short tandem repeat profiling was used to confirm the uniqueness of the cell lines against databases of known cell lines and mutations were assessed using Sequenom. The expression of thyroid-specific genes was examined using real-time PCR. Tumorigenicity was determined using an orthotopic thyroid xenograft tumor mouse model.
RESULTS: Six PTC cell lines (five conventional PTCs and one follicular variant of PTC) were generated and found to be unique when compared by short tandem repeat profiling against databases of all existing cell lines. The five conventional PTC cell lines carry the BRAF V600E mutation and the follicular variant of PTC cell line had an NRAS mutation. Five of the six cell lines had a mutation in the promoter of the human telomerase reverse transcriptase gene. None of the cell lines have RET/PTC rearrangements. Three cell lines were tumorigenic in the orthotopic thyroid xenograft tumor mouse model.
CONCLUSIONS: These five characterized conventional PTC cell lines and the unique follicular variant of PTC cell line should be valuable reagents for thyroid cancer research. The three tumorigenic cell lines can be used for in vivo testing of targeted therapeutic and novel agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427145      PMCID: PMC4318904          DOI: 10.1210/jc.2014-2624

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Frequency of TERT promoter mutations in human cancers.

Authors:  João Vinagre; Ana Almeida; Helena Pópulo; Rui Batista; Joana Lyra; Vasco Pinto; Ricardo Coelho; Ricardo Celestino; Hugo Prazeres; Luis Lima; Miguel Melo; Adriana Gaspar da Rocha; Ana Preto; Patrícia Castro; Ligia Castro; Fernando Pardal; José Manuel Lopes; Lúcio Lara Santos; Rui Manuel Reis; José Cameselle-Teijeiro; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

2.  R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway.

Authors:  Chenli Lin; Yinji Liang; Huili Zhu; Jijun Zhang; Xueyun Zhong
Journal:  Neurosci Lett       Date:  2012-09-19       Impact factor: 3.046

3.  BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.

Authors:  Ji Young Park; Wook Youn Kim; Tae Sook Hwang; Sang Sook Lee; Hyunkyung Kim; Hye Seung Han; So Dug Lim; Wan Seop Kim; Young Bum Yoo; Kyoung Sik Park
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

4.  RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.

Authors:  Nikhil Gupta; Anil K Dasyam; Sally E Carty; Marina N Nikiforova; N Paul Ohori; Michaele Armstrong; Linwah Yip; Shane O LeBeau; Kelly L McCoy; Christopher Coyne; Michael T Stang; Jonas Johnson; Robert L Ferris; R Seethala; Yuri E Nikiforov; Steven P Hodak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

5.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

6.  Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.

Authors:  Ji Yun Yun; Young A Kim; Ji-Young Choe; Hyesook Min; Kyu Sang Lee; Youngho Jung; Sohee Oh; Ji Eun Kim
Journal:  J Clin Pathol       Date:  2013-08-28       Impact factor: 3.411

7.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

Authors:  Xiaoli Liu; Justin Bishop; Yuan Shan; Sara Pai; Dingxie Liu; Avaniyapuram Kannan Murugan; Hui Sun; Adel K El-Naggar; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-07-12       Impact factor: 5.678

8.  Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2.

Authors:  Valeria Carina; Giovanni Zito; Giuseppe Pizzolanti; Pierina Richiusa; Angela Criscimanna; Vito Rodolico; Laura Tomasello; Maria Pitrone; Walter Arancio; Carla Giordano
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

9.  Detection of thyroid cancer stem cells in papillary thyroid carcinoma.

Authors:  Soon-Hyun Ahn; Ying C Henderson; Michelle D Williams; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2013-12-03       Impact factor: 5.958

10.  Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.

Authors:  Marina N Nikiforova; Abigail I Wald; Somak Roy; Mary Beth Durso; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

View more
  13 in total

1.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

2.  Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Authors:  Iñigo Landa; Nikita Pozdeyev; Christopher Korch; Laura A Marlow; Robert C Smallridge; John A Copland; Ying C Henderson; Stephen Y Lai; Gary L Clayman; Naoyoshi Onoda; Aik Choon Tan; Maria E R Garcia-Rendueles; Jeffrey A Knauf; Bryan R Haugen; James A Fagin; Rebecca E Schweppe
Journal:  Clin Cancer Res       Date:  2019-02-08       Impact factor: 12.531

3.  Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.

Authors:  Thao N D Pham; Krishan Kumar; Brian T DeCant; Meng Shang; Samad Z Munshi; Maria Matsangou; Kazumi Ebine; Hidayatullah G Munshi
Journal:  Mol Cancer Ther       Date:  2018-11-16       Impact factor: 6.261

4.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

5.  Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2.

Authors:  Rengyun Liu; Jie Tan; Xiaopei Shen; Ke Jiang; Chaoqun Wang; Guangwu Zhu; Mingzhao Xing
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

6.  Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.

Authors:  Jennifer A Morrison; Laura A Pike; Greg Lund; Qiong Zhou; Brittelle E Kessler; Kevin T Bauerle; Sharon B Sams; Bryan R Haugen; Rebecca E Schweppe
Journal:  Horm Cancer       Date:  2015-03-24       Impact factor: 3.869

7.  Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity.

Authors:  Thao Nd Pham; Christina Spaulding; Mario A Shields; Anastasia E Metropulos; Dhavan N Shah; Mahmoud G Khalafalla; Daniel R Principe; David J Bentrem; Hidayatullah G Munshi
Journal:  JCI Insight       Date:  2022-05-09

8.  Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1.

Authors:  Thao N D Pham; Sophie Stempel; Mario A Shields; Christina Spaulding; Krishan Kumar; David J Bentrem; Maria Matsangou; Hidayatullah G Munshi
Journal:  Int J Mol Sci       Date:  2019-09-02       Impact factor: 5.923

9.  A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.

Authors:  Ying C Henderson; Abdallah S R Mohamed; Anastasios Maniakas; Yunyun Chen; Reid T Powell; Shaohua Peng; Maria Cardenas; Michelle D Williams; Diana Bell; Mark E Zafereo; Rui Jennifer Wang; Steve E Scherer; David A Wheeler; Maria E Cabanillas; Marie-Claude Hofmann; Faye M Johnson; Clifford C Stephan; Vlad Sandulache; Stephen Y Lai
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

10.  Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.

Authors:  Anastasios Maniakas; Ying C Henderson; Hu Hei; Shaohua Peng; Yunyun Chen; Yujie Jiang; Shuangxi Ji; Maria Cardenas; Yulun Chiu; Diana Bell; Michelle D Williams; Marie-Claude Hofmann; Steve E Scherer; David A Wheeler; Naifa L Busaidy; Ramona Dadu; Jennifer R Wang; Maria E Cabanillas; Mark Zafereo; Faye M Johnson; Stephen Y Lai
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.